GT Biopharma, Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $3.5M-40.1% | $5.8M-10.3% | $6.5M-26.6% | $8.8M |
| Selling, general and administrative (including $432,000 and $230,000 of stock compensation during the years ended December 31, 2025 and 2024, respectively) | $8.9M+4.5% | $8.6M+20.5% | $7.1M-42.9% | $12.4M |
| Loss from Operations | -$12.4M+13.5% | -$14.4M-5.8% | -$13.6M+36.1% | -$21.3M |
| Interest income | $123K-69.4% | $402K-48.5% | $780K+367.1% | -$292K |
| Interest expense | -$127K | — | — | $8K |
| Loss on initial recognition of Greenshoe Rights liability | -$28.7M | — | — | — |
| Change in fair value of Greenshoe Rights liability | $11.4M | — | — | — |
| Change in fair value of warrant liability | $241K-69.9% | $800K-83.3% | $4.8M+4131.1% | -$119K |
| Gain on settlement of vendor payable | $998K | — | — | — |
| Other | $156K | — | — | — |
| Total Other Income (Expense), Net | -$15.9M-1425.5% | $1.2M-79.9% | $6.0M+1702.9% | -$373K |
| Net Loss | -$28.4M-115.4% | -$13.2M-73.3% | -$7.6M+63.6% | -$20.9M |
| Dividend on Series L Preferred Stock | -$320K | — | — | — |
| Deemed dividend | -$5.8M | — | — | — |
| Net Loss attributable to common stockholders’ | -$34.4M-161.7% | -$13.2M | — | — |
| Net Loss Per Share - Basic | -$6.68+3.7% | -$6.94-23.0% | -$5.64+100.0% | -$19660.00 |
| Net Loss Per Share - Diluted | -$6.68+3.7% | -$6.94-23.0% | -$5.64+100.0% | -$19660.00 |
| Weighted average common shares outstanding - basic | 5.5M+190.6% | 1.9M+40.8% | 1.3M-99.9% | 1.06B |
| Weighted average common shares outstanding - diluted | 5.5M+190.6% | 1.9M-99.9% | 1.35B+26.9% | 1.06B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.